RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ResMed Inc. (RMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive analyst sentiment, and upcoming expansion plans, making it a solid choice for long-term investment despite neutral technical indicators.
The technical indicators are neutral to slightly bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 50.899, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 254.287, R1: 260.598, S1: 247.975, R2: 264.498, S2: 244.076.
ResMed Inc. plans to hire over 100 employees at a new facility, positively impacting the local economy.
The company plans to launch a new center in 2027 to enhance its U.S. market presence.
Strong Q2 financial performance with double-digit revenue and earnings growth.
Analysts have raised price targets, with Citi setting a target of $345 and RBC Capital at $314, reflecting confidence in the stock's potential.
Neutral insider and hedge fund trading trends, indicating no strong institutional support recently.
Bearish technical indicators suggest short-term weakness.
Some analysts remain cautious with Neutral or Hold ratings, citing potential risks like competitor expansion and decelerating revenue growth in the future.
In Q2 2026, ResMed reported strong financials: Revenue increased by 10.98% YoY to $1.42 billion, Net Income grew by 13.92% YoY to $392.59 million, EPS rose by 14.53% YoY to $2.68, and Gross Margin improved by 5.52% YoY to 60.93%.
Analyst sentiment is generally positive. Citi raised its price target to $345 with a Buy rating, and RBC Capital raised its target to $314 with an Outperform rating. However, some analysts like Piper Sandler and Baird maintain Neutral ratings, citing modest growth and potential risks.
